Reviva Pharmaceuticals (RVPH) Competitors $0.46 0.00 (-0.11%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.45 -0.01 (-2.67%) As of 05:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. BMEA, COYA, ANEB, TCRX, VTGN, ATOS, MGNX, OKYO, XBIT, and ANIXShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Biomea Fusion (BMEA), Coya Therapeutics (COYA), Anebulo Pharmaceuticals (ANEB), TScan Therapeutics (TCRX), VistaGen Therapeutics (VTGN), Atossa Genetics (ATOS), MacroGenics (MGNX), OKYO Pharma (OKYO), XBiotech (XBIT), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Its Competitors Biomea Fusion Coya Therapeutics Anebulo Pharmaceuticals TScan Therapeutics VistaGen Therapeutics Atossa Genetics MacroGenics OKYO Pharma XBiotech Anixa Biosciences Reviva Pharmaceuticals (NASDAQ:RVPH) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of RVPH or BMEA? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 18.4% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, RVPH or BMEA? Reviva Pharmaceuticals has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Which has higher earnings & valuation, RVPH or BMEA? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.71Biomea FusionN/AN/A-$138.43M-$3.03-0.63 Do analysts recommend RVPH or BMEA? Reviva Pharmaceuticals currently has a consensus price target of $5.20, suggesting a potential upside of 1,029.70%. Biomea Fusion has a consensus price target of $14.80, suggesting a potential upside of 670.83%. Given Reviva Pharmaceuticals' higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Biomea Fusion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17 Is RVPH or BMEA more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -259.17% Biomea Fusion N/A -243.95%-140.74% Does the media favor RVPH or BMEA? In the previous week, Biomea Fusion had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for Biomea Fusion and 3 mentions for Reviva Pharmaceuticals. Biomea Fusion's average media sentiment score of 0.96 beat Reviva Pharmaceuticals' score of 0.33 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBiomea Fusion beats Reviva Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.34M$2.51B$5.78B$9.79BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-0.7122.8231.2726.59Price / SalesN/A550.89433.65155.40Price / CashN/A177.0937.7359.36Price / Book-46.036.1810.176.68Net Income-$29.92M$32.94M$3.27B$265.59M7 Day Performance-14.52%-0.78%1.39%0.62%1 Month Performance-2.02%2.77%6.19%2.61%1 Year Performance-56.58%12.01%43.79%22.34% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.6699 of 5 stars$0.46-0.1%$5.20+1,029.7%-54.4%$31.34MN/A-0.715BMEABiomea Fusion3.5649 of 5 stars$1.74+0.6%$16.80+865.5%-74.5%$102.95MN/A-0.5750Analyst ForecastGap DownCOYACoya Therapeutics1.8403 of 5 stars$6.01-2.3%$16.50+174.5%+11.5%$102.86M$3.55M-4.856Analyst RevisionANEBAnebulo Pharmaceuticals2.3531 of 5 stars$2.58+3.2%$5.50+113.2%+38.0%$102.71MN/A-9.924Positive NewsTCRXTScan Therapeutics3.426 of 5 stars$1.79-0.6%$7.80+335.8%-68.0%$101.86M$2.82M-1.64100Positive NewsVTGNVistaGen Therapeutics1.2877 of 5 stars$3.40+2.7%N/A-8.2%$101.55M$490K-1.9140Positive NewsATOSAtossa Genetics2.7047 of 5 stars$0.79+1.7%$6.17+680.6%-45.4%$100.30MN/A-3.438Positive NewsMGNXMacroGenics4.3723 of 5 stars$1.52-3.8%$3.60+136.8%-50.7%$99.68M$149.96M-2.67430Positive NewsOKYOOKYO Pharma3.1491 of 5 stars$2.41-9.1%$7.00+190.5%+109.2%$99.67MN/A0.007Positive NewsXBITXBiotech1.6281 of 5 stars$3.20+1.6%N/A-49.3%$96.04M$4.01M-3.48100News CoveragePositive NewsANIXAnixa Biosciences2.4818 of 5 stars$2.98+0.3%$9.00+202.0%-8.5%$95.67M$210K-7.845Upcoming Earnings Related Companies and Tools Related Companies BMEA Alternatives COYA Alternatives ANEB Alternatives TCRX Alternatives VTGN Alternatives ATOS Alternatives MGNX Alternatives OKYO Alternatives XBIT Alternatives ANIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access